Home › Funds › Affinity Asset Advisors, LLC › SYRE

Affinity Asset Advisors, LLC position in SYRE

SPYRE THERAPEUTICS INC · Health Care

Affinity Asset Advisors, LLC reported holding 1,279,134 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$113.9M, representing 5.30% of its reported portfolio and ranking #3 among its reported holdings. Affinity Asset Advisors, LLC has disclosed SYRE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.28M sh
Reported value held$113.88M
Portfolio Weight5.30%
First reportedQ3 2023
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Affinity Asset Advisors, LLC's SYRE position evolved

Affinity Asset Advisors, LLC first disclosed a stake in SYRE in Q3 2023 at 242,297 shares (US$3.0M). The position peaked in Q3 2026 at 1,279,134 shares, worth US$113.9M. Across 13 filings, Affinity Asset Advisors, LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,279,134 shares valued at US$113.9M. Notable position changes include a 114% increase in Q4 2023 (shares rose 9% over the following quarter), a 65% increase in Q4 2024 (shares fell 31% over the following quarter), a 134% increase in Q3 2025 (shares rose 95% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 242.30K $2.97M New
Q4 2023 517.55K $11.14M Add
Q1 2024 410.00K $15.55M Reduce
Q2 2024 513.42K $12.07M Add
Q3 2024 498.42K $14.66M Reduce
Q4 2024 824.33K $19.19M Add
Q1 2025 481.68K $7.77M Reduce
Q2 2025 606.68K $9.08M Add
Q3 2025 1.42M $23.79M Add
Q4 2025 1.43M $46.93M Add
Q1 2026 1.28M $64.52M Reduce
Q2 2026 1.28M $113.56M Hold
Q3 2026 1.28M $113.88M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 65 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has Affinity Asset Advisors, LLC held SYRE?

Affinity Asset Advisors, LLC has disclosed SYRE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Affinity Asset Advisors, LLC's current position in SYRE?

As of Q3 2026, Affinity Asset Advisors, LLC holds 1.28M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $113.88M, representing 5.30% of its reported portfolio and ranking #3.

Has Affinity Asset Advisors, LLC been buying or selling SYRE?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in SYRE. The position peaked in Q3 2026 at 1.28M shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 65 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.